Table 4.
Proviral integration in the pim loci and cooperating oncogenes after M-MuLV infection of transgenic mice.
| Transgenic model | Integration site | Phenotype and latency (non-infected versus infected with M-MuLV) |
|---|---|---|
| Eμ-pim1 | c-myc (81%) | T-cell lymphomas |
| N-myc (19%) | From 10 to 92% penetrance | |
| pal1 (93%) | From 22 to 7–8 weeks average latency (22, 25, 73) | |
| frat1 (17%) (transplanted infected tumors) | ||
| Pim1−/−a | pim2 (25%) | T-cell lymphomas with 100% penetrance |
| c-myc or N-myc (28%) | From 14 to 18 weeks average latency (11) | |
| Eμ-c-myc | pim1 (31%) | B-cell lymphomas |
| bmi1 (35%) | From 80 to 100% incidence | |
| pal1 (28%) | From 18 to 7 weeks average latency (10) | |
| bla1 (14%) | ||
| Eμ-c-myc; Pim1−/− | pim2 (80%) | B-cell lymphoma |
| No differences in penetrance (100%) or latency (50 days) (11) | ||
| Eμ-c-myc; Pim2−/− | pim1 (40%) | Mature B-cell lymphoma |
| No differences in penetrance or latency (30) | ||
| Eμ-c-myc; Pim1−/−;Pim2−/− | pim3 (24%) | Mature B-cell lymphoma |
| Tpl2 (18.4%) | From 21 weeks of latency to 24 weeks of latency (30, 59) | |
| cyclin D-2 (13%) | ||
| c-kit (8%) | ||
| Dkmi1 (5%) | ||
| Dkmi9 (8%) | ||
| Dkmi11 (5%) | ||
| Dkmi15 (10.5%) | ||
| Dkmi20 (8%) | ||
| Dkmi28 (10.5%) | ||
| Eμ-L-myc; Eμ-pim1b | pal1/gfi1 (37–75%) | T-cell lymphomas with 100% penetrance |
| Tiam1 (12%) | From 14 to 8.5 weeks average latency (50, 73) | |
| bla1 (8.5%) | ||
| CD2-myc | pim1 (4–7.7%) | Lymphoblastic thymic lymphomas |
| til1 (32%) | From 3–33 to 100% penetrance | |
| ahi1 (2.5%) | From 4 to 1 months average latency (51 –53) | |
| Eμ-v-abl 40 | c-myc (21%) | From plastocytomas to disseminated lymphoma |
| N-myc (21%) | From 60 to 100% penetrance | |
| pim1 + c-myc or N-myc (14%) | From 10 to 7 weeks average latency (60) | |
| Eμ-bcl2 | c-myc (26%) | From pre-B-cell lymphoma and plastocytoma to clonal pre-B-, B-, and immature T-lymphoma |
| pim1 (6%) | From 3–15 to 100% penetrance | |
| pim2 (23%) | From up to 53 to 19 weeks average latency (61, 74) | |
| Eμ-Bmi1 | N or c-myc (39%) | B- and T-cell lymphoma with 100% penetrance |
| pim1 or 2 (31%) | From 18–25 to 9 weeks average latency (48) | |
| Tet-o-BCL6; EμSR-tTa–c | pim1 (21%) | From splenic B-cell lymphomas to T- and B-cell lymphomas |
| From 6 to 45.3% penetrance | ||
| From 26 to 11.5 weeks average latency (57, 58) | ||
| E2a-pbx1 | pim1 (48%) | Diffuse high-grade T-cell lymphomas with 100% penetrance |
| pim2 (0%) | From 18 to 11.5 weeks average latency (65) | |
| c-myc or N-myc (5%) | ||
| CD2-runx2 | c-myc and/or N-myc (82%) | Thymic lymphoma |
| pim1 (21%) | From 6 to 100% penetrance | |
| pal1 (39–44%) | From 53 to 14 weeks (55) | |
| Increased levels of Pim1 w/o proviral integration in the pim-1 locus | ||
| Eμ-pp-frat1 | c-myc (37–50%) | From no tumors to 100% development of T-cell lymphoma between 11 and 14 weeks (67) |
| N-myc (6%) | ||
| pim1/pim2 (23%) | ||
| gif1/pal1 (18%) | ||
| Rag2−/− | pim1 (50%) | From no tumors to 80% lymphomas with a latency of 21 weeks (69) |
| pim2 (0%) | ||
| p53−/− | pim1 (25%) only in p53+/− | Thymomas with 100% penetrance |
| From 26 to 13 weeks average latency (68) |
aIn this case, the comparison is carried out between pim1-expressing and infected pim-null mice.
bInfection with wild-type and sup-F M-MuLV.
cInfection with MOL4070LTR.